composite end point 6-month follow -up [clinicaltrials_resource:94a469a2adfb91dfac6deb12e3968502]
death, reinfarction, coronary interventions (PCI and/or CABG) due to new ACS or exacerbation of angina, symptoms of heart failure, rehospitalisation due to cardiovascular events and stroke in context of HGF concentration in acute stage of ACS
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
composite end point 6-month follow -up [clinicaltrials_resource:94a469a2adfb91dfac6deb12e3968502]
death, reinfarction, coronary interventions (PCI and/or CABG) due to new ACS or exacerbation of angina, symptoms of heart failure, rehospitalisation due to cardiovascular events and stroke in context of HGF concentration in acute stage of ACS
Bio2RDF identifier
94a469a2adfb91dfac6deb12e3968502
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:94a469a2adfb91dfac6deb12e3968502
measure [clinicaltrials_vocabulary:measure]
composite end point
time frame [clinicaltrials_vocabulary:time-frame]
6-month follow -up
description
death, reinfarction, coronary ...... ntration in acute stage of ACS
identifier
clinicaltrials_resource:94a469a2adfb91dfac6deb12e3968502
title
composite end point 6-month follow -up
@en
type
label
composite end point 6-month fo ...... 469a2adfb91dfac6deb12e3968502]
@en